Prebiotic trial reports symptom improvement in constipation-predominant IBS
Symptoms and quality-of-life scores improved within the prebiotic group, but the abstract leaves the size of any advantage over placebo unclear.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
A mixture of inulin and oligofructose was studied in adults with constipation-predominant IBS. Symptom severity and quality-of-life scores improved within the prebiotic group. However, those changes alone do not show how much benefit came from the supplement compared with placebo. The abstract also does not report results from the depression scale.
This abstract-based summary concerns a small trial. Placebo results for overall symptom severity and quality of life are missing, and the practical importance of the score changes is unclear.
What researchers found
IBS Symptom Severity Score
Within-group change during the 8-week trial; lower scores mean less severe symptoms. Placebo change and a between-group estimate are not reported.
What was measured
Researchers repeatedly assessed stool form, bowel symptoms, IBS-related quality of life and depression. Because the intervention combined inulin and oligofructose, its results cannot identify how much either ingredient contributed to the reported changes.
Why the comparison matters
The constipation rating had a statistically significant group-by-time result, comparing how groups changed over the study. That offers comparative evidence, but the abstract does not give a clear between-group effect size for this measure.
The original publication
A randomized trial of inulin for bowel symptoms, depression and quality of life in constipation predominant IBS.
Akçalı Ç, Uçar A, Atay K
Sci Rep · 2025
- PubMed ID
- 41034384
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.